Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham prognostic index up to 5 years after breast cancer diagnosis

Journal of Clinical Oncology

Volumn 28, Issue 27, 2010, Pages 4129-4134

  Van Belle, Vanya ^a   Van Calster, Ben ^a   Brouckaert, Olivier ^a   Bempt, Isabelle Vanden ^a   Pintens, Saskia ^a   Harvey, Vernon ^a   Murray, Paula ^a   Naume, Björn ^a   Wiedswang, Gro ^a   Paridaens, Robert ^a   Moerman, Philippe ^a   Amant, Frederic ^a   Leunen, Karin ^a   Smeets, Ann ^a   Drijkoningen, Maria ^a   Wildiers, Hans ^a   Christiaens, Marie Rose ^a   Vergote, Ignace ^a   Van Huffel, Sabine ^a   Neven, Patrick ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; HER2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NEW ZEALAND; NORWAY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; BELGIUM; BREAST TUMOR; CHEMISTRY; CLINICAL TRIAL; FEMALE; GENETICS; HEALTH SURVEY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; VALIDATION STUDY;

AGED; BELGIUM; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HEALTH STATUS INDICATORS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEW ZEALAND; NORWAY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77957971149     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.4200     Document Type: Article

References (43)

1. Ferlay J, Autier P, Boniol M, et al: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592, 2007
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics 2009. CA Cancer J Clin 59:225-249, 2009
3. Galea M, Blamey R, Elsto C, et al: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207-219, 1992
4. Lee AH, Ellis IO: The Nottingham prognostic index for invasive carcinoma of the breast. Pathol Oncol Res 14:116-115, 2008
5. D'Eredita G, Giardina C, Martellotta M, et al: Prognostic factors in breast cancer: The predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 37:591-596, 2001 (Pubitemid 32261016)
6. Blamey RW, Ellis IO, Pinder SE, et al: Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 43:1548-1555, 2007
7. Bueno-de-Mesquita J, van Harten W, Retel V, et al: Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: A prospective community-based feasibility study (RASTER). Lancet Oncol 8:1079-1087, 2007
8. Liu R, Wang X, Chen GY, et al: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356:217-226, 2007 (Pubitemid 46143225)
9. Neven P, Van Belle V, Brouckaert O, et al: Are gene signatures better than traditional clinical factors? Lancet Oncol 9:197-198, 2008
10. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235:177-182, 1987 (Pubitemid 17231334)
11. Ross J, Fletcher J: The HER2/neu oncogene in breast cancer: Prognostic factor, predictive factor and target for therapy. Oncologist 3:237-252, 1998
12. Pichon M, Broet P, Magdelenat H, et al: Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 73:1545-1551, 1996 (Pubitemid 26235381)
13. Cui X, Schiff R, Arpino G, et al: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23:7721-7735, 2005 (Pubitemid 46291836)
14. Collett K, Skjaerven R, Maehle B: The prognostic contribution of estrogen and progesterone receptor status to a modified version of the Nottingham Prognostic Index. Breast Cancer Res Treat 48:1-9, 1998 (Pubitemid 28073528)
15. Dunnwald LK, Rossing MA, Li CI: Hormone receptor status, tumor characteristics, and prognosis: A prospective cohort of breast cancer patients. Breast Cancer Res 9:R6, 2007
16. De Maeyer L, Van Limbergen E, De Nys K, et al: Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol 26:335-336, 2008
17. Elston C, Ellis I: Pathological prognostic factors in breast cancer: The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19:403-410, 1991
18. Brouckaert O, Pintens S, Van Belle V, et al: Short-term outcome of primary operated early breast cancer by hormone and HER2 receptors. Breast Cancer Res Treat 115:349-358, 2009
19. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007 (Pubitemid 350003059)
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Cox DR: Regression models and life-tables (with discussion). Journal of the Royal Statistical Society 34:197-220, 1972
22. Schwarz G: Estimating the dimension of a model. Annals of Statistics 6:461-464, 1978
23. Efron B, Tibshirani RJ: Improvements on cross-validation: The 632+ bootstrap method. J Am Stat Asso 92:548-560, 1997
24. Harrell F, Klee K, Califf R, et al: Regression modeling strategies for improved prognostic prediction. Stat Med 95:634-635, 1984
25. Janes H, Pepe M, Gu W: Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med 149:751-760, 2008
26. Pencina M, D' Agostino R Sr, D' Agostino R Jr, et al: Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27:157-172, 2008 (Pubitemid 351193639)
27. Heagerty P, Lumley T, Pepe M: Time-dependent roc curves for censored survival data and a diagnostic marker. Biometrics 56:337-344, 2000 (Pubitemid 30422619)
28. Graf E, Schmoor C, Sauerbrei W, et al: Assessment and comparison of prognostic classification schemes for survival data, Stat Med 18:2529-2545, 1999 (Pubitemid 29423514)
29. Efron B, Tibshirani R: Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statistical Science 1:54-75, 1986
30. Siddique J, Harel O: MIDAS: A SAS macro for multiple imputation using distance-aided selection of donors. Journal of Statistical Software, American Statistical Association 29:1-18, 2009
31. Reference deleted
32. Rampaul RS, Pinder SE, Elston CW, et al: Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham Breast Team. Eur J Surg Oncol 27:229-238, 2001 (Pubitemid 32621745)
33. Hawkins RA, Tesdale AL, Prescott RJ, et al: Outcome after extended follow-up in a prospective study of operable breast cancer: Key factors and a prognostic index. Br J Cancer 87:8-14, 2002
34. Charpin C, Garcia S, Bonnier P, et al: Bcl-2 automated quantitative immunocytochemical assays in breast carcinomas: Correlation with 10-year follow-up. J Clin Oncol 16:2025-2031, 1998 (Pubitemid 28265036)
35. Callagy GM, Pharoah PD, Pinder SE, et al: Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 12:2468-2475, 2006
36. Malmstrom P, Bendahl PO, Boiesen P, et al: S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 19:2010-2019, 2001
37. Gonzalez MA, Pinder SE, Callagy G, et al: Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol 21:4306-4313, 2003 (Pubitemid 46628462)
38. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
39. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
40. Eden P, Ritz C, Rose C, et al: "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40:1837-1841, 2004
41. Reference deleted
42. Keyomarsi K, Tucker SL, Buchholz TA, et al: Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566-1575, 2002 (Pubitemid 35315837)
43. Pritchard KI, Shepherd L, O'Malley FP, et al: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111, 2006 (Pubitemid 43736610)